Evidence map›Paper›PMID 33704911›Full record

ArticlePediatric blood & cancer2021

Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia.

Azada Ibrahimova, Lena E Winestone, Tamara P Miller, Kyle Kettler, Alix E Seif, Yuan-Shung Huang, Caitlin W Elgarten, Regina M Myers, Brian T Fisher, Richard Aplenc and 1 more

Open access · greenAbstract read
In one paragraph

Article in Pediatric blood & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Azada IbrahimovaDepartment of Pediatrics and Adolescent Medicine, Einstein Healthcare Network Philadelphia, Philadelphia, Pennsylvania, USA.
Lena E WinestoneDivision of AIBMT, Department of Pediatrics, UCSF Benioff Children's Hospital, San Francisco, California, USA.
Tamara P MillerAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Kyle KettlerDrexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Alix E SeifDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Yuan-Shung HuangCenter for Pediatric Clinical Effectiveness, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Caitlin W ElgartenDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Regina M MyersDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Brian T FisherCenter for Pediatric Clinical Effectiveness, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Richard AplencDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Kelly D GetzDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-2020-5153
Children's Hospital of Philadelphia · USDrexel University · USEinstein Healthcare Network · USEmory University · USUCSF Benioff Children's Hospital · US

Funding

Improving Adverse Event Reporting on Cooperative Oncology Group TrialsK07CA211956 · NCI · EMORY UNIVERSITY · PI MILLER, TAMARA PORTER · 2017 to 2022
$916k
Early Treatment-Related Cardiotoxicity and Subsequent Outcomes in Pediatric Acute Myeloid Leukemia: an Assessment of Development, Progression and MitigationK01HL143153 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GETZ, KELLY DIRINGER · 2018 to 2022
$716k
NCI NIH HHS K07 CA211956NHLBI NIH HHS K01 HL143153
6 · The paper itself

Abstract

backgroundTreatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group.

methodsIn retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis.

resultsAnalyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants.

conclusionsInfants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.

Indexed as

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsChildHospitals, PediatricHumansInfantRetrospective Studiesinduction mortalityinfant leukemiaresource utilization

Identifiers

PMID33704911
PMCPMC8283996
OpenAlexW3133932873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.